Financials in USD. Standardized financial statements.
A compact view of how Kazia Therapeutics Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $42,000 | $2.31M | $555 | $10,000 | $15.18M | $988,110 | $1,565 | $13,108 | $8.79M | $4.07M |
| Revenue Growth? | -98.2% | +415755.9% | -94.5% | -99.9% | +1436.6% | +63038.0% | -88.1% | -99.9% | +115.9% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $42,000 | $2.31M | $555 | $10,000 | $15.18M | $988,110 | $1,565 | $13,108 | $8.79M | $4.07M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $14.26M | $30.77M | $24.12M | $25.41M | $21.56M | $13.18M | $10.25M | $14.69M | $19.66M | $15.64M |
| Operating Income? | -$14.22M | -$28.46M | -$24.12M | -$25.40M | -$6.38M | -$12.20M | -$8.38M | -$12.49M | -$10.85M | -$12.77M |
| EBITDA? | -$13.28M | -$26.59M | -$22.28M | -$23.52M | -$5.11M | -$11.11M | -$7.71M | -$10.81M | -$9.44M | -$11.72M |
| Income Before Tax | -$22.45M | -$27.05M | -$20.74M | -$25.38M | -$8.90M | -$12.77M | -$10.57M | -$6.34M | -$10.87M | -$12.15M |
| Income Tax Expense | -$1.75M | -$271,000 | -$271,092 | -$368,000 | -$484,000 | -$298,195 | -$298,000 | -$305,000 | -$198,544 | $2.77M |
| Net Income? | -$20.70M | -$26.78M | -$20.47M | -$25.01M | -$8.42M | -$12.47M | -$10.27M | -$6.04M | -$10.67M | -$12.06M |
| EPS? | $-18.90 | $-55.00 | $-55.00 | $-95.00 | $-35.80 | $-80.00 | $-85.60 | $-59.80 | $-109.30 | $-135.20 |
| Diluted EPS? | $-18.90 | $-55.00 | $-55.00 | $-95.00 | $-35.80 | $-80.00 | $-85.60 | $-59.80 | $-109.30 | $-135.20 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality